FLT3 inhibition in acute myeloid leukaemia

British Journal of Haematology

Volumn 138, Issue 6, 2007, Pages 687-699

  Knapper, Steven ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Acute myeloid leukaemia; FMS like tyrosine kinase 3; Inhibitors; Tyrosine kinase

Indexed keywords

17 AAG; 17 N ALLYLAMINO 17 DEMETHOXYL GELDANAMYCIN; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; ABT 869; AG 2043; AGL 2033; AGL 2043; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; CEP 701; CHIR 258; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; FMS LIKE TYROSINE KINASE INHIBITOR; HEAT SHOCK PROTEIN 90 INHIBITOR; HERBIMYCIN A; IMATINIB; KI 23819; KW 2449; MIDOSTAURIN; PROTEIN TYROSINE KINASE INHIBITOR; QUINOXALINE DERIVATIVE; RETINOIC ACID; SEMAXANIB; SORAFENIB; SU 11657; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BONE PAIN; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; EDEMA; ENZYME ACTIVATION; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE REACTION; KIDNEY CARCINOMA; LEUKEMOGENESIS; LUNG INFILTRATE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; THROMBOSIS; TREATMENT RESPONSE;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; FMS-LIKE TYROSINE KINASE 3; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LEUKEMIA, MYELOID; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION;

EID: 34548181032     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06700.x     Document Type: Review

References (89)

1. Armstrong, S.A., Staunton, J.E., Silverman, L.B., Pieters, R., Den Boer, M.L., Minden, M.D., Sallan, S.E., Lander, E.S., Golub, T.R. Korsmeyer, S.J. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genetics, 30, 41 47.
2. Armstrong, S.A., Kung, A.L., Mabon, M.E., Silverman, L.B., Stam, R.W., Den Boer, M.L., Pieters, R., Kersey, J.H., Sallan, S.E., Fletcher, J.A., Golub, T.R., Griffin, J.D. Korsmeyer, S.J. (2003) Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell, 3, 173 183.
3. Armstrong, S.A., Mabon, M.E., Silverman, L.B., Li, A., Gribben, J.G., Fox, E.A., Sallan, S.E. Korsmeyer, S.J. (2004) FLT3 mutations in childhood acute lymphoblastic leukemia. Blood, 103, 3544 3546.
4. Birg, F., Courcoul, M., Rosnet, O., Bardin, F., Pebusque, M.J., Marchetto, S., Tabilio, A., Mannoni, P. Birnbaum, D. (1992) Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood, 80, 2584 2593.
5. Brown, P., Meshinchi, S., Levis, M., Alonzo, T.A., Gerbing, R., Lange, B., Arceci, R. Small, D. (2004) Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood, 104, 1841 1849.
6. Brown, P., Levis, M., Shurtleff, S., Campana, D., Downing, J. Small, D. (2005a) FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood, 105, 812 820.
7. Brown, P., Levis, M., McIntyre, E., Griesemer, M. Small, D. (2005b) Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Blood, 106, 2467a.
8. Carow, C.E., Levenstein, M., Kaufmann, S.H., Chen, J., Amin, S., Rockwell, P., Witte, L., Borowitz, M.J., Civin, C.I. Small, D. (1996) Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood, 87, 1089 1096.
9. Choudhary, C., Schwable, J., Brandts, C., Tickenbrock, L., Sargin, B., Kindler, T., Fischer, T., Berdel, W.E., Muller-Tidow, C. Serve, H. (2005) AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood, 106, 265 273.
10. Clark, J.J., Cools, J., Curley, D.P., Yu, J.C., Lokker, N.A., Giese, N.A. Gilliland, D.G. (2004) Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood, 104, 2867 2872.
11. Cools, J., Mentens, N., Furet, P., Fabbro, D., Clark, J.J., Griffin, J.D., Marynen, P. Gilliland, D.G. (2004) Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Research, 64, 6385 6389.
12. DeAngelo, D., Stone, R., Heaney, M.L., Nimer, S.D., Paquette, R., Bruner-Klisovic, R., Caligiuri, M.A., Cooper, M.R., LeCerf, J.-M., Karol, M., Heinrich, M.C. Druker, B. (2004) Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia bearing a FLT3 internal tandem duplication mutation. Blood, 104, 1792a.
13. DeAngelo, D.J., Stone, R.M., Heaney, M.L., Nimer, S.D., Paquette, R.L., Klisovic, R.B., Caligiuri, M.A., Cooper, M.R., Lecerf, J.M., Karol, M.D., Sheng, S., Holford, N., Curtin, P.T., Druker, B.J. Heinrich, M.C. (2006) Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood, 108, 3674 3681.
14. Drexler, H.G. (1996) Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia, 10, 588 599.
15. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R. Talpaz, M. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine, 344, 1038 1042.
16. Fiedler, W., Mesters, R., Tinnefeld, H., Loges, S., Staib, P., Duhrsen, U., Flasshove, M., Ottmann, O.G., Jung, W., Cavalli, F., Kuse, R., Thomalla, J., Serve, H., O'Farrell, A.M., Jacobs, M., Brega, N.M., Scigalla, P., Hossfeld, D.K. Berdel, W.E. (2003) A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood, 102, 2763 2767.
17. Fiedler, W., Serve, H., Dohner, H., Schwittay, M., Ottmann, O.G., O'Farrell, A.M., Bello, C.L., Allred, R., Manning, W.C., Cherrington, J.M., Louie, S.G., Hong, W., Brega, N.M., Massimini, G., Scigalla, P., Berdel, W.E. Hossfeld, D.K. (2005) A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 105, 986 993.
18. Gazit, A., Yee, K., Uecker, A., Bohmer, F.D., Sjoblom, T., Ostman, A., Waltenberger, J., Golomb, G., Banai, S., Heinrich, M.C. Levitzki, A. (2003) Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorganic and Medicinal Chemistry, 11, 2007 2018.
19. George, P., Bali, P., Cohen, P., Tao, J., Guo, F., Sigua, C., Vishvanath, A., Fiskus, W., Scuto, A., Annavarapu, S., Moscinski, L. Bhalla, K. (2004) Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Research, 64, 3645 3652.
20. Giles, F.J., Stopeck, A.T., Silverman, L.R., Lancet, J.E., Cooper, M.A., Hannah, A.L., Cherrington, J.M., O'Farrell, A.M., Yuen, H.A., Louie, S.G., Hong, W., Cortes, J.E., Verstovsek, S., Albitar, M., O'Brien, S.M., Kantarjian, H.M. Karp, J.E. (2003) SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood, 102, 795 801.
21. Gilliland, D.G. Griffin, J.D. (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood, 100, 1532 1542.
22. Gotze, K.S., Ramirez, M., Tabor, K., Small, D., Matthews, W. Civin, C.I. (1998) Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. Blood, 91, 1947 1958.
23. Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M., Lu, F., Lippke, J. Saxena, K. (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Molecular Cell, 13, 169 178.
24. Griswold, I.J., Shen, L.J., La Rosee, P., Demehri, S., Heinrich, M.C., Braziel, R.M., McGreevey, L., Haley, A.D., Giese, N., Druker, B.J. Deininger, M.W. (2004) Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood, 104, 2912 2918.
25. Grundler, R., Thiede, C., Miething, C., Steudel, C., Peschel, C. Duyster, J. (2003) Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood, 102, 646 651.
26. Grundler, R., Miething, C., Thiede, C., Peschel, C. Duyster, J. (2005) FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood, 105, 4792 4799.
27. Hawley, T.S., Fong, A.Z., Griesser, H., Lyman, S.D. Hawley, R.G. (1998) Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand. Blood, 92, 2003 2011.
28. Heidel, F., Solem, F.K., Breitenbuecher, F., Lipka, D.B., Kasper, S., Thiede, M.H., Brandts, C., Serve, H., Roesel, J., Giles, F., Feldman, E., Ehninger, G., Schiller, G.J., Nimer, S., Stone, R.M., Wang, Y., Kindler, T., Cohen, P.S., Huber, C. Fischer, T. (2006) Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood, 107, 293 300.
29. Hortobagyi, G.N. (2001) Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Seminars in Oncology, 28, 43 47.
30. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., Druker, B., Goldman, J., O'Brien, S.G., Russell, N., Fischer, T., Ottmann, O., Cony-Makhoul, P., Facon, T., Stone, R., Miller, C., Tallman, M., Brown, R., Schuster, M., Loughran, T., Gratwohl, A., Mandelli, F., Saglio, G., Lazzarino, M., Russo, D., Baccarani, M. Morra, E. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New England Journal of Medicine, 346, 645 652.
31. Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L. Gilliland, D.G. (2002a) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood, 99, 310 318.
32. Kelly, L.M., Kutok, J.L., Williams, I.R., Boulton, C.L., Amaral, S.M., Curley, D.P., Ley, T.J. Gilliland, D.G. (2002b) PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proceedings of the National Academy of Sciences of the United States of America, 99, 8283 8288.
33. Kelly, L.M., Yu, J.C., Boulton, C.L., Apatira, M., Li, J., Sullivan, C.M., Williams, I., Amaral, S.M., Curley, D.P., Duclos, N., Neuberg, D., Scarborough, R.M., Pandey, A., Hollenbach, S., Abe, K., Lokker, N.A., Gilliland, D.G. Giese, N.A. (2002c) CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 1, 421 432.
34. Knapper, S., Mills, K.I., Gilkes, A.F., Austin, S.J., Walsh, V. Burnett, A.K. (2006a) The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood, 108, 3494 3503.
35. Knapper, S., Burnett, A.K., Littlewood, T., Kell, W.J., Agrawal, S., Chopra, R., Clark, R., Levis, M.J. Small, D. (2006b) A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood, 108, 3262 3270.
36. Komeno, Y., Kurokawa, M., Imai, Y., Takeshita, M., Matsumura, T., Kubo, K., Yoshino, T., Nishiyama, U., Kuwaki, T., Kubo, K., Osawa, T., Ogawa, S., Chiba, S., Miwa, A. Hirai, H. (2005) Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. Leukemia, 19, 930 935.
37. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752 1759.
38. Kottaridis, P.D., Gale, R.E. Linch, D.C. (2003) Flt3 mutations and leukaemia. British Journal of Haematology, 122, 523 538.
39. Lavagna-Sevenier, C., Marchetto, S., Birnbaum, D. Rosnet, O. (1998) FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia, 12, 301 310.
40. Levis, M. Small, D. (2003a) FLT3: ITDoes matter in leukemia. Leukemia, 17, 1738 1752.
41. Levis, M. Small, D. (2003b) Novel FLT3 tyrosine kinase inhibitors. Expert Opinion on Investigational Drugs, 12, 1951 1962.
42. Levis, M., Tse, K.F., Smith, B.D., Garrett, E. Small, D. (2001) A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood, 98, 885 887.
43. Levis, M., Allebach, J., Tse, K.F., Zheng, R., Baldwin, B.R., Smith, B.D., Jones-Bolin, S., Ruggeri, B., Dionne, C. Small, D. (2002) A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood, 99, 3885 3891.
44. Levis, M., Pham, R., Smith, B.D. Small, D. (2004) In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood, 104, 1145 1150.
45. Levis, M., Murphy, K.M., Pham, R., Kim, K.T., Stine, A., Li, L., McNiece, I., Smith, B.D. Small, D. (2005a) Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood, 106, 673 680.
46. Levis, M., Smith, B.D., Beran, M., Baer, M.R., Erba, H.P., Cripe, L., Coutre, S., Advani, A., Perl, A., Devetten, M., Stuart, R., Tallman, M., Brown, P., Tremmel, L. Small, D. (2005b) A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. Blood, 106, 403a.
47. Levis, M., Brown, P., Smith, B.D., Stine, A., Pham, R., Stone, R., Deangelo, D., Galinsky, I., Giles, F., Estey, E., Kantarjian, H., Cohen, P., Wang, Y., Roesel, J., Karp, J.E. Small, D. (2006) Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood, 108, 3477 3483.
48. Li, Y., Li, H., Wang, M.N., Lu, D., Bassi, R., Wu, Y., Zhang, H., Balderes, P., Ludwig, D.L., Pytowski, B., Kussie, P., Piloto, O., Small, D., Bohlen, P., Witte, L., Zhu, Z. Hicklin, D.J. (2004) Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood, 104, 1137 1144.
49. Lierman, E., Lahortiga, I., Van, M.H., Mentens, N., Marynen, P. Cools, J. (2007) The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica, 92, 27 34.
50. Lopes de Menezes, D.E., Peng, J., Garrett, E.N., Louie, S.G., Lee, S.H., Wiesmann, M., Tang, Y., Shephard, L., Goldbeck, C., Oei, Y., Ye, H., Aukerman, S.L. Heise, C. (2005) CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clinical Cancer Research, 11, 5281 5291.
51. Lowenberg, B., Downing, J.R. Burnett, A. (1999) Acute myeloid leukemia. New England Journal of Medicine, 341, 1051 1062.
52. Marchetto, S., Fournier, E., Beslu, N., Aurran-Schleinitz, T., Dubreuil, P., Borg, J.P., Birnbaum, D. Rosnet, O. (1999) SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia, 13, 1374 1382.
53. McKenna, H.J., Stocking, K.L., Miller, R.E., Brasel, K., De Smedt, T., Maraskovsky, E., Maliszewski, C.R., Lynch, D.H., Smith, J., Pulendran, B., Roux, E.R., Teepe, M., Lyman, S.D. Peschon, J.J. (2000) Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood, 95, 3489 3497.
54. Mead, A., Linch, D.C., Hills, R., Wheatley, K., Burnett, A.K. Gale, R.E. (2005) Favourable prognosis associated with FLT3 tyrosine kinase domain mutations in AML in contrast to the adverse outcome associated with intermal tandem duplications. Blood, 106, 334a.
55. Meshinchi, S., Woods, W.G., Stirewalt, D.L., Sweetser, D.A., Buckley, J.D., Tjoa, T.K., Bernstein, I.D. Radich, J.P. (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood, 97, 89 94.
56. Minami, Y., Kiyoi, H., Yamamoto, Y., Yamamoto, K., Ueda, R., Saito, H. Naoe, T. (2002) Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia, 16, 1535 1540.
57. Morgan, G.J., Parker, A., Cavet, J., Cavenaugh, J., Heise, C. Garzon, F. (2005) A phase I trial of CHIR-258, a multitargeted RTK inhibitor, in acute myeloid leukemia (AML). Blood, 106, 2794a.
58. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T. Misawa, S. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 10, 1911 1918.
59. O'Farrell, A.M., Abrams, T.J., Yuen, H.A., Ngai, T.J., Louie, S.G., Yee, K.W., Wong, L.M., Hong, W., Lee, L.B., Town, A., Smolich, B.D., Manning, W.C., Murray, L.J., Heinrich, M.C. Cherrington, J.M. (2003a) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, 101, 3597 3605.
60. O'Farrell, A.M., Foran, J.M., Fiedler, W., Serve, H., Paquette, R.L., Cooper, M.A., Yuen, H.A., Louie, S.G., Kim, H., Nicholas, S., Heinrich, M.C., Berdel, W.E., Bello, C., Jacobs, M., Scigalla, P., Manning, W.C., Kelsey, S. Cherrington, J.M. (2003b) An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clinical Cancer Research, 9, 5465 5476.
61. O'Farrell, A.M., Yuen, H.A., Smolich, B., Hannah, A.L., Louie, S.G., Hong, W., Stopeck, A.T., Silverman, L.R., Lancet, J.E., Karp, J.E., Albitar, M., Cherrington, J.M. Giles, F.J. (2004) Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leukemia Research, 28, 679 689.
62. Piloto, O., Levis, M., Huso, D., Li, Y., Li, H., Wang, M.N., Bassi, R., Balderes, P., Ludwig, D.L., Witte, L., Zhu, Z., Hicklin, D.J. Small, D. (2005) Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. Cancer Research, 65, 1514 1522.
63. Piloto, O., Nguyen, B., Huso, D., Kim, K.T., Li, Y., Witte, L., Hicklin, D.J., Brown, P. Small, D. (2006) IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Research, 66, 4843 4851.
64. Piloto, O., Wright, M., Brown, P., Kim, K.T., Levis, M. Small, D. (2007) Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood, 109, 1643 1652.
65. Rosnet, O., Schiff, C., Pebusque, M.J., Marchetto, S., Tonnelle, C., Toiron, Y., Birg, F. Birnbaum, D. (1993) Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood, 82, 1110 1119.
66. Rosnet, O., Buhring, H.J., Marchetto, S., Rappold, I., Lavagna, C., Sainty, D., Arnoulet, C., Chabannon, C., Kanz, L., Hannum, C. Birnbaum, D. (1996) Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia, 10, 238 248.
67. Rusten, L.S., Lyman, S.D., Veiby, O.P. Jacobsen, S.E. (1996) The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro. Blood, 87, 1317 1325.
68. Sawyers, C.L. (2002) Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell, 1, 413 415.
69. Shankar, D.B., Li, J., Tapang, P., Owen, M.J., Pease, L.J., Dai, Y., Wei, R.Q., Albert, D.H., Bouska, J.J., Osterling, D.J., Guo, J., Marcotte, P.A., Johnson, E.F., Soni, N., Hartandi, K., Michaelides, M.R., Davidsen, S.K., Priceman, S.J., Chang, J.C., Rhodes, K., Shah, N., Moore, T.B., Sakamoto, K.M. Glaser, K.B. (2007) ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood, 109, 3400 3408.
70. Shih, L.Y., Huang, C.F., Wu, J.H., Lin, T.L., Dunn, P., Wang, P.N., Kuo, M.C., Lai, C.L. Hsu, H.C. (2002) Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood, 100, 2387 2392.
71. Shih, L.Y., Huang, C.F., Wu, J.H., Wang, P.N., Lin, T.L., Dunn, P., Chou, M.C., Kuo, M.C. Tang, C.C. (2004) Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples. Clinical Cancer Research, 10, 1326 1332.
72. Small, D., Levenstein, M., Kim, E., Carow, C., Amin, S., Rockwell, P., Witte, L., Burrow, C., Ratajczak, M.Z. Gewirtz, A.M. (1994) STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proceedings of the National Academy of Sciences of the United States of America, 91, 459 463.
73. Smith, B.D., Levis, M., Beran, M., Giles, F., Kantarjian, H., Berg, K., Murphy, K.M., Dauses, T., Allebach, J. Small, D. (2004) Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood, 103, 3669 3676.
74. Sohal, J., Phan, V.T., Chan, P.V., Davis, E.M., Patel, B., Kelly, L.M., Abrams, T.J., O'Farrell, A.M., Gilliland, D.G., Le Beau, M.M. Kogan, S.C. (2003) A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood, 101, 3188 3197.
75. Stam, R.W., Den Boer, M.L., Schneider, P., Nollau, P., Horstmann, M., Beverloo, H.B., de Voort, E.V., Valsecchi, M.G., de Lorenzo, P., Sallan, S.E., Armstrong, S.A. Pieters, R. (2005) Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood, 106, 2484 2490.
76. Stirewalt, D.L. Radich, J.P. (2003) The role of FLT3 in haematopoietic malignancies. Nature Reviews. Cancer, 3, 650 665.
77. Stirewalt, D.L., Kopecky, K.J., Meshinchi, S., Engel, J.H., Pogosova-Agadjanyan, E.L., Linsley, J., Slovak, M.L., Willman, C.L. Radich, J.P. (2006) Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood, 107, 3724 3726.
78. Stone, R., Fischer, T., Paquette, R., Schiller, G., Schiffer, C., Ehninger, G., Cortes, J., Kantarjian, H., de Angelo, D., Yu, R., Zhang, L., Cohen, P., Wang, Y., Phillips, P. Giles, F. (2005a) Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. Blood, 106, 404a.
79. Stone, R.M., DeAngelo, D.J., Klimek, V., Galinsky, I., Estey, E., Nimer, S.D., Grandin, W., Lebwohl, D., Wang, Y., Cohen, P., Fox, E.A., Neuberg, D., Clark, J., Gilliland, D.G. Griffin, J.D. (2005b) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 105, 54 60.
80. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326 4335.
81. Tse, K.F., Allebach, J., Levis, M., Smith, B.D., Bohmer, F.D. Small, D. (2002) Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia, 16, 2027 2036.
82. Wadleigh, M., DeAngelo, D.J., Griffin, J.D. Stone, R.M. (2005) After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood, 105, 22 30.
83. Weisberg, E., Boulton, C., Kelly, L.M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D.G. Griffin, J.D. (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell, 1, 433 443.
84. Whitman, S.P., Archer, K.J., Feng, L., Baldus, C., Becknell, B., Carlson, B.D., Carroll, A.J., Mrozek, K., Vardiman, J.W., George, S.L., Kolitz, J.E., Larson, R.A., Bloomfield, C.D. Caligiuri, M.A. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research, 61, 7233 7239.
85. Yamamoto, Y., Kiyoi, H., Nakano, Y., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., Yagasaki, F., Shimazaki, C., Akiyama, H., Saito, K., Nishimura, M., Motoji, T., Shinagawa, K., Takeshita, A., Saito, H., Ueda, R., Ohno, R. Naoe, T. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 97, 2434 2439.
86. Yee, K.W., O'Farrell, A.M., Smolich, B.D., Cherrington, J.M., McMahon, G., Wait, C.L., McGreevey, L.S., Griffith, D.J. Heinrich, M.C. (2002) SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood, 100, 2941 2949.
87. Yee, K.W., Schittenhelm, M., O'Farrell, A.M., Town, A.R., McGreevey, L., Bainbridge, T., Cherrington, J.M. Heinrich, M.C. (2004) Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood, 104, 4202 4209.
88. Zhao, M., Kiyoi, H., Yamamoto, Y., Ito, M., Towatari, M., Omura, S., Kitamura, T., Ueda, R., Saito, H. Naoe, T. (2000) In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia, 14, 374 378.
89. Zheng, R., Levis, M., Piloto, O., Brown, P., Baldwin, B.R., Gorin, N.C., Beran, M., Zhu, Z., Ludwig, D., Hicklin, D., Witte, L., Li, Y. Small, D. (2004) FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood, 103, 267 274.